AVSF - American Gene Technologies 2022, LLC is a venture capital fund based in Boston, Massachusetts. According to its most recent Form D, filed Oct 25, 2022, it has sold $1,543,297 of interests to 103 investors since its first sale in Oct 2022. The minimum investment it accepts from an outside investor is $5,000. It relies on the Section 3(c)(1) exclusion, which limits it to 100 beneficial owners, typically accredited investors. The offering uses Rule 506(b), which does not permit general solicitation. Related persons named in the filing include Michael Collins.
- Total raised
- $1,543,297Cumulative sales reported on Form D
- Investors
- 103
- First sale
- Oct 10, 2022
- Minimum investment
- $5,000
- Who can invest
- Accredited investorsSection 3(c)(1): up to 100 beneficial owners
- Offering exemption
- Rule 506(b)No general advertising
- Key people and entities
- Michael Collins
- Latest Form D
- Oct 25, 2022
From SEC filings, not verified. This page republishes the fund's Form D as filed. It is not an offer, solicitation or recommendation, and AltMountain has not reviewed the fund. “Raised” is cumulative sales, not current assets or performance. Returns are not part of SEC filings. Private funds are speculative, illiquid and generally limited to accredited investors or qualified purchasers. Full disclosures · Request a correction
Questions about AVSF - American Gene Technologies 2022, LLC
What is the minimum investment for AVSF - American Gene Technologies 2022, LLC?
According to its latest Form D, filed Oct 25, 2022, the minimum investment AVSF - American Gene Technologies 2022, LLC accepts from an outside investor is $5,000.
Who can invest in AVSF - American Gene Technologies 2022, LLC?
AVSF - American Gene Technologies 2022, LLC is generally open only to accredited investors, and it may have no more than 100 beneficial owners because it relies on Section 3(c)(1). It uses Rule 506(b), which does not allow general advertising.
How much has AVSF - American Gene Technologies 2022, LLC raised?
AVSF - American Gene Technologies 2022, LLC reports $1,543,297 sold from 103 investors on its Form D filed Oct 25, 2022. This is cumulative sales since the offering began, not current assets or performance.
Where is AVSF - American Gene Technologies 2022, LLC based?
AVSF - American Gene Technologies 2022, LLC is based in Boston, Massachusetts.
When did AVSF - American Gene Technologies 2022, LLC launch?
AVSF - American Gene Technologies 2022, LLC reports its first sale in Oct 2022.
Size compared with every venture capital fund
Raised more than 69% of the 535 venture capital funds based in Massachusetts, and more than 67% of all 14,864 that report sales.